FOUNDERS

Carrick Therapeutics was founded by Drs. Elaine Sullivan, Ash Bahl, Ed Ainscow and founding investors with the aim of building the leading European based oncology company with a world class innovative R&D pipeline focusing on targeting key pathways in cancer progression and adaptive resistance.

BOARD OF DIRECTORS
& BOARD OBSERVERS

Carrick Therapeutics’ Board of Directors combines expertise from the pharmaceutical industry and the investment community with the shared goal of improving the lives of cancer patients.

Dr. Steven Gillis
ARCH Venture Partners

TBC
University of Cambridge Enterprise

Dr. Tom Hulme
Google Ventures

Mr. Jason Lettmann
Lightstone Ventures

Dr. Elaine Sullivan
Carrick Therapeutics

Dr. Robert Tansley
Cambridge Innovation Capital

Mr. Paul Thurk
ARCH Venture Partners

SCIENTIFIC ADVISORY BOARD

Carrick Therapeutics is collaborating with world-class cancer researchers from Cambridge, Oxford, London, and Ireland to defeat cancer.

Sir John Bell
Chairman of Scientific Advisory Board, Carrick Therapeutics
University of Oxford

Professor Chas Bountra
University of Oxford

Professor Johann DeBono
Royal Marsden Hospital

Professor William Gallagher
University College Dublin

Professor Steve Jackson
University of Cambridge

Professor Peter Johnson
University of Southampton

Professor David Kerr
University of Oxford

Professor Michael O’Dwyer
National University of Ireland (Galway)

Doctor Anthony Quinn
Boston

Professor John Robertson
University of Nottingham